MOORESVILLE, N.C. — Biohaven Pharmaceuticals announced that Nurtec® ODT will extends its sponsorship for the second year as the primary partner for the No. 51 Rick Ware Racing entry during the entire NASCAR Cup Series Season and the NTT INDYCAR Series, after a successful first season. Nurtec ODT is the first and only FDA-approved medication that’s proven to both treat and prevent migraine attacks.
“We had a great season with Biohaven, Nurtec ODT and Cody (Ware) this past year,” said Team Owner Rick Ware. “The company and brand values align perfectly with Rick Ware Racing, and we could not be more excited to have them as a primary partner in 2022. Heading into this season, we are looking forward to elevating our on-track performance and continuing to support our racing fans, including people with migraine and the military community through our Military Salutes Program.”
Cody Ware has competed within all forms of motorsports throughout his career including NASCAR, INDYCAR, IMSA, Asian Le Mans Series and Motorcycles. In 2021, C. Ware made his NTT INDYCAR Series debut at Road America, as well as competing full-time in the NASCAR Cup Series for Rick Ware Racing.
“I am thrilled to be back behind the wheel of the No. 51 Nurtec ODT car, which holds personal meaning for me as a person with migraine,” said Cody Ware. “With the new cars this year and the Ford alliance, I am looking forward to seeing what the future holds for the Rick Ware Racing team. Nurtec ODT has been a great partner this past year, helping to raise awareness of migraine among NASCAR fans, and 2022 looks to be another promising year of racing!”
Takuma Sato, two-time INDY 500 Champion, joined the No. 51 team in December to compete full-time in the NTT INDYCAR Series.